Trans-Pacific Multicenter Collaborative Study of Minimally Invasive Proximal Versus Total Gastrectomy for Proximal Gastric and Gastroesophageal Junction Cancers
Part of paid clinical trials in Rochester, Minnesota.
- Sponsor
- M.D. Anderson Cancer Center
- Study ID
- NCT05205343
- Status
- Recruiting
Conditions
- Gastric
- GastroEsophageal Cancer
- Gastrostomy
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Standard of Care — OTHERcomplete a questionnaire within 30 days before your surgery and then at 1, 3, 6, and 12 months after surgery
- Control Group — OTHERcomplete a questionnaire within 30 days before your surgery and then at 1, 3, 6, and 12 months after surgery
Study Details
To compare the symptoms of patients who have a MIPG to the symptoms of patients who have a MITG.
Key Dates
- Start date
- May 11, 2022
- Status verified
- Feb 2026
- Primary completion
- May 31, 2026
- Completion
- May 31, 2026
Study Design
- Enrollment
- 20 participants (estimated)
Arms
- Arm: Standard of Carequestionnaire within 30 days before your surgery and then at 1, 3, 6, and 12 months after surgery. The questionnaire will ask about your health, appetite, and quality of life. It should take about 3-5 minutes to complete.
- Arm: Control groupquestionnaire within 30 days before your surgery and then at 1, 3, 6, and 12 months after surgery. The questionnaire will ask about your health, appetite, and quality of life. It should take about 3-5 minutes to complete.
Primary Outcome Measure
(MDASI-GI) MD Anderson Symptom Inventory Questionnaire [ Time Frame: 3 months after surgery ]
Central Contacts
- Naruhiko Ikoma, MD(832) 729-2675
Locations (2)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Mayo Clinic in Rochester | Rochester | Minnesota | 55905 | - |
| M D Anderson Cancer Center | Houston | Texas | 77030 | Naruhiko Ikoma, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Rochester, MN
Related Studies
- Feasibility of a Constant Pressure Skin Disk (CPSD) in Enteral Tubes.Recruiting · Mayo Clinic · Rochester, Minnesota
- Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL AdenocarcinomaPHASE2 · Recruiting · Harry H Yoon · Rochester, Minnesota
- Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid TumorsPHASE1/PHASE2 · Recruiting · ModeX Therapeutics, An OPKO Health Company · Denver, Colorado
- A Phase 2 Study of Zanidatamab in Patients With HER2-expressing TumorsPHASE2 · Recruiting · Jazz Pharmaceuticals · Prescott, Arizona